Skip to main content
. 2021 Aug 5;39(38):5376–5384. doi: 10.1016/j.vaccine.2021.07.093

Table 2.

Characteristics of acute respiratory illness since March 1, 2020 in seropositive or seronegative individuals.

Seropositive (n = 14) Seronegative (n = 143)
Fever ≥ 38◦C – n (%) 7 (50) 45 (31.5)
Chills – n (%) 7 (50) 57 (39.9)
Fatigue – n (%) 11 (78.6) 96 (67.1)
Muscle aches – n (%) 7 (50) 45 (31.5)
Sore throat – n (%) 5 (35.7) 88 (61.5)
Cough – n (%) 6 (42.9) 100 (69.9)
Runny nose – n (%) 8 (57.1) 99 (69.2)
Difficulty breathing – n (%) 5 (35.6) 34 (23.8)
Shortness of breath – n (%) 4 (28.6) 22 (15.4)
Chest pain – n (%) 4 (28.6) 29 (20.3)
Other respiratory symptoms – n (%) 2 (14.3) 21 (14.7)
Headache – n (%) 10 (71.4) 75 (52.4)
Nausea/vomiting – n (%) 0 17 (11.9)
Stomach ache – n (%) 2 (14.3) 19 (13.3)
Diarrhea – n (%) 5 (35.7) 32 (22.4)
Sought medical attention – n (%) 8 (57.1) 90 (62.9)
Missed work or school – n (%) 8 (57.1) 61 (42.7)
Hospitalizeda – n (%) 3 (21.4) 7 (4.9)
a

Only difference between the proportion of hospitalized patients between seropositive and seronegative individuals was statistically significant (p = 0.047).